Nature CommunicationsCancer BiologyPeer-reviewed journal article
Persister state-directed transitioning and vulnerability in melanoma
H. Chauvistre, B. Shannan, S. M. Daignault, R. J. Ju, D. Picard, S. Egetemaier, R. Varaljai, A. Sechi, F. Kaschani, O. Keminer, S. J. Stehbens, Q. Liu, X. Yin, K. Jeyakumar, F. C. E. Vogel, C. Krepler, V. W. Rebecca, L. Kubat, S. S. Lueong, J. Forster, S. Horn, M. Remke, M. Ehrmann, A. Paschen, J. C. Becker, , A. Roesch
Abstract
Melanoma is a highly plastic tumor characterized by dynamic interconversion of different cell identities depending on the biological context. For example, melanoma cells with high expression of the H3K4 demethylase KDM5B (JARID1B) rest in a slow-cycling, yet reversible persister state. Over time, KDM5Bhigh cells can promote rapid tumor repopulation with equilibrated KDM5B expression heterogeneity. The cellular identity of KDM5Bhigh persister cells has not been studied so far, missing an important cell state-directed treatment opportunity in melanoma. Here, we have established a doxycycline-titratable system for genetic induction of permanent intratumor expression of KDM5B and screened for chemical agents that phenocopy this effect. Transcriptional profiling and cell functional assays confirmed that the dihydropyridine phenoxyethyl 4-(2-fluorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexa-hydro-quinoline-3-carboxylate (termed Cpd1) supports high KDM5B expression and directs melanoma cells towards differentiation along the melanocytic lineage and to cell cycle-arrest. The high KDM5B state additionally prevents cell proliferation through negative regulation of cytokinetic abscission. Moreover, treatment with Cpd1 promoted the expression of the melanocyte-specific tyrosinase gene specifically sensitizing melanoma cells for the tyrosinase-processed antifolate prodrug 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin (TMECG). In summary, our study provides proof-of-concept for a new dual hit strategy in melanoma, in which persister state-directed transitioning limits tumor growth and plasticity and primes melanoma cells towards lineage-specific elimination.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Redirecting resistance evolution in BRAFV600 melanoma by inhibition of the peroxiredoxin-thioredoxin system
Stefanie Egetemaier, Heike Chauvistré, … Alexander Roesch·bioRxiv·Mar 10, 2025
- TFIIH kinase CDK7 antagonizes phenotype switching and emergence of drug tolerance in melanoma
P. Berico, m. cigrang, … F. Coin·bioRxiv·Sep 24, 2020
- Midkine Drives Reawakening of Dormant Melanoma Metastases
Carolina Rodríguez-Tirado, Thoufiqul Alam Riaz, … María Soledad Sosa·bioRxiv·May 27, 2025
- A Transient Metabolic State In Melanoma Persister Cells Mediated By Chemotherapeutic Treatments
P. Karki, V. Angardi, … M. Orman·bioRxiv·Feb 21, 2021
- A CD24+CD271+ Melanoma Cancer Stem Cell Possesses Hybrid Characteristics of its Single Marker Counterparts and Promotes Invasion and Therapeutic Resistance
O. Knowles, P. Doldan, … A. Biddle·bioRxiv·Jun 7, 2023
- Prospective isolation according to melanin pigment content of melanoma cells with heterogeneous potentials for disease propagation
C. Fedele, G. Kuser Abali, … M. Shackleton·bioRxiv·Oct 31, 2022